Nye farmakologiske behandlingsmodaliteter ved type 2-diabetes

TY - JOUR

T1 - Nye farmakologiske behandlingsmodaliteter ved type 2-diabetes

AU - Madsbad, Sten

AU - Hermansen, Kjeld

PY - 2012/9

Y1 - 2012/9

N2 - The variable pathogenesis and progressive nature of type 2 diabetes emphasise the need for new antidiabetic treatments. The long acting glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors have improved the treatment. Novel approaches include inhibitors of sodium glucose co-transporter 2, which increase renal glucose elimination, G-protein-coupled receptor agonists, which potentiate insulin and incretin hormone secretion. Proof of principle has been shown for glucagon receptor agonists, glucokinase activators and treatment with dual intestinal peptides, which all induce weight loss and improve glucose tolerance.

AB - The variable pathogenesis and progressive nature of type 2 diabetes emphasise the need for new antidiabetic treatments. The long acting glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors have improved the treatment. Novel approaches include inhibitors of sodium glucose co-transporter 2, which increase renal glucose elimination, G-protein-coupled receptor agonists, which potentiate insulin and incretin hormone secretion. Proof of principle has been shown for glucagon receptor agonists, glucokinase activators and treatment with dual intestinal peptides, which all induce weight loss and improve glucose tolerance.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 174

SP - 2143

EP - 2146

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 37

ER -